Initial and sustained phases of myogenic response of rat mesenteric small arteries.
A possible role for a metabolite of cytochrome P-450 omega-hydroxylase in the initial and sustained phases of the myogenic response in cannulated rat mesenteric small arteries was studied. With slight preconstriction (norepinephrine and neuropeptide Y), pressure was raised from 60 to 100 mmHg, and both initial (within 2 min) and sustained phases (at 10 min) of the myogenic response were quantified. The myogenic response was fully inhibited by D600 (methoxyverapamil). Ketoconazole and 17-octadecanoic acid did not affect the initial phase but inhibited the sustained phase. In contrast, miconazole did not affect either phase. Charybdotoxin and iberiotoxin potentiated the initial phase but eliminated the sustained phase. Apamin, glibenclamide, 4-aminopyridine, and barium had no effect on either phase. The results demonstrate different mechanisms for the initial and sustained phases of the myogenic response of rat mesenteric small arteries. Only the sustained phase appears mediated through a cytochrome P-450 omega-hydroxylase metabolite and calcium-activated K+ channels. However, both phases of the response are dependent on calcium influx through voltage-dependent calcium channels.
Chlopicki
S
S
Department of Pharmacology, University of Aarhus, 8000 Aarhus C, Denmark. mfschlop@cyf-kr.edu
Nilsson
H
H
Mulvany
M J
MJ
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D018999:Charybdotoxin / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D005711:Gallopamil / Q000494:pharmacology; D006706:Homeostasis / Q000502:physiology; D008297:Male; D008638:Mesenteric Arteries / Q000502:physiology*; D009478:Neuropeptide Y / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D002121:Calcium Channel Blockers; D005231:Fatty Acids, Unsaturated; D009478:Neuropeptide Y; D010455:Peptides; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D014662:Vasoconstrictor Agents; D018999:Charybdotoxin; D016718:Arachidonic Acid; C047008:17-octadecynoic acid; D005711:Gallopamil; C064719:iberiotoxin; D001189:Aryl Hydrocarbon Hydroxylases; D002118:Calcium; D009638:Norepinephrine